Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The company narrowed its full-year revenue guidance to a range of $2.335 billion to $2.355 billion and adjusted EBITDA guidance to $307 million to $317 million
Some of the most notable findings include: LEADER Trial (Liraglutide) This study found that liraglutide reduced the risk of major cardiovascular events by 13% in patients with type 2 diabetes
Why Everyone's Talking About GLP-1 Drugs Youve probably heard the names: Ozempic, Wegovy , and Mounjaro
Daily fluctuations are normal on a GLP-1, especially after a step-up
A novel peptide, using Saccharomyces cerevisiae (yeast) as a biological host, engineered to naturally activate the body's GLP-1 pathway the same pathway regulated by leading GLP-1 options
